Effects of LY333334 [recombinant human parathyroid hormone (1-34)] and alendronate sodium on markers of bone metabolism in postmenopausal women with osteoporosis.

被引：0
|
作者：
Body, JJ
Gaich, GA
Scheele, WH
Kulkarni, PM
Hodsman, AB
机构：
[1] Free Univ Brussels, Inst Jules Bordet, Brussels, Belgium
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Colorado Ctr Bone Res, Lakewood, CO USA
[4] St Josephs Hlth Care, London, England
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2001年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S530 / S530
页数：1
相关论文
共 50 条
  • [41] Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure
    Jiang, YB
    Zhao, JJ
    Mitlak, BH
    Wang, OH
    Genant, HK
    Eriksen, EF
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (11) : 1932 - 1941
  • [42] Distinctive effects of teriparatide [rhPTH(1-34)] and alendronate on bone turnover and lumbar spine bone density in women with osteoporosis
    McClung, MR
    Miller, PD
    Civitelli, R
    Warren, ML
    Greenspan, SL
    Tamayo, JA
    Donley, DW
    San Martin, J
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S18 - S18
  • [43] Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure
    Frolik, CA
    Black, EC
    Cain, RL
    Satterwhite, JH
    Brown-Augsburger, PL
    Sato, M
    Hock, JM
    BONE, 2003, 33 (03) : 372 - 379
  • [44] Single and Combined use of Human Parathyroid Hormone (PTH) (1-34) on Areal Bone Mineral Density (aBMD) in Postmenopausal Women with Osteoporosis: Evidence Based on 9 RCTs
    Song, Jiefu
    Jing, Zhizhen
    Chang, Feng
    Li, Lijun
    Su, Yunxing
    MEDICAL SCIENCE MONITOR, 2014, 20 : 2624 - 2632
  • [45] Does human parathyroid hormone (hPTS 1-34) treatment increase vertebral size in postmenopausal women with glucocorticoid-induced osteoporosis (GIOP)
    Behman, Q
    Lang, T
    Modin, GW
    Genant, HK
    Lane, NE
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S379 - S379
  • [46] The reduced risk of new vertebral fracture persists for up to 18 months following treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone (1-34).
    Lindsay, R
    Scheele, WH
    Clancy, AD
    Mitlak, BH
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S379 - S379
  • [47] COMPARISON OF THE EFFECTS OF INTERMITTENT AND CONTINUOUS ADMINISTRATION OF HUMAN PARATHYROID HORMONE(1-34) ON RAT BONE
    UZAWA, T
    HORI, M
    EJIRI, S
    OZAWA, H
    BONE, 1995, 16 (04) : 477 - 484
  • [48] Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats
    Sato, M
    Zeng, GQ
    Turner, CH
    ENDOCRINOLOGY, 1997, 138 (10) : 4330 - 4337
  • [49] Effects of Intermittent Parathyroid Hormone 1-34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic Women
    Tang, Yutao
    Xia, Han
    Kang, Liang
    Sun, Quan
    Su, Zhe
    Hao, Congqiang
    Xue, Yuan
    MEDICAL SCIENCE MONITOR, 2019, 25 : 259 - 268
  • [50] A Comparison of Parathyroid Hormone-Related Protein (1-36) and Parathyroid Hormone (1-34) on Markers of Bone Turnover and Bone Density in Postmenopausal Women: The PrOP Study (vol 28, pg 2266, 2013)
    Horwitz, Mara J.
    Augustine, Marilyn
    Khan, Leila
    Martin, Emily
    Oakley, Christine C.
    Carneiro, Raquel M.
    Tedesco, Mary Beth
    Laslavic, Angela
    Sereika, Susan M.
    Bisello, Alessandro
    Garcia-Ocana, Adolfo
    Gundberg, Caren M.
    Cauley, Jane A.
    Stewart, Andrew F.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 (03) : 770 - 770
12345